Because the synergistic effect of CD36 inhibitors and immunotherapy has generated much interest as a new therapeutic strategy, CD36 may be a potential therapeutic target for cancer therapy as a central regulator for tumor progression and immune evasion in tumor-bearing hosts. This evidence concerns the gene CD36 and neoplasm.